Metabolomics in drug discovery: The missing piece for multi-omics data

Posted In: Events

April 13th
11:00 am EDT/17:00 CEST

Scientists are increasingly using metabolomics together with other omics tools to better inform and enable critical decision-making across the various phases of the drug discovery and development process.

Experts will discuss how the integration of metabolomics with other omics data streams enables R&D programs to:

  • Support target identification, mechanism of action and biomarker discovery
  • Evaluate pharmacokinetics / pharmacodynamics relationships for design of optimal dosing strategy
  • Understand the heterogeneity of patient populations
  • Understand disease progression and drug efficacy
  • Inform on potential drug repurposing

Subject Matter Experts:

  • Luca A Lotta, MD, Ph.D., Vice President and Head, Cardiovascular Metabolic and Musculoskeletal Therapeutic Area Genetics, Regeneron Genetics Center (RGC), Regeneron Pharmaceuticals Inc. in New York (USA)
  • Richard Beger, Ph.D., Branch Chief, Omics, Modeling, Imaging and Chemistry (OMIC) Branch, NCTR, FDA
  • Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer, Metabolon

Contact Us

Talk with an expert

Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1711

+1 (919) 572-1721

International Headquarters

Metabolon GmbH

Zeppelinstraße 3
85399 Hallbergmoos

+49 89 99017752
This site is registered on as a development site.